Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia [Yahoo! Finance]
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: Yahoo! Finance
- Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-label extension (OLE) long-term safety trial expected in Q4 2024 - CUPERTINO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today it has gained alignment with the U.S. Food and Drug Administration (FDA) on its registrational Phase 3 program for brilaroxazine in schizophrenia. The FDA accepted a 4-week RECOVER-2 study for brilaroxazine in schizophrenia. Notably, the FDA also indicated that two positive Phase 3 studies showing efficacy at week 4 that are accompanied by long-term safety data of at least 12 months could be supportive of an NDA submi
Show less
Read more
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH GlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHPR Newswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH Accesswire
- RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHBusiness Wire
- REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
RVPH
Earnings
- 11/14/23 - Miss
RVPH
Sec Filings
- 4/15/24 - Form 8-K
- 4/15/24 - Form 10-K
- 4/15/24 - Form 8-K
- RVPH's page on the SEC website